<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Nautilus Biotechnology Inc — News on 6ix</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc</link>
<description>Latest news and press releases for Nautilus Biotechnology Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 12:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/nautilus-biotechnology-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835a07578dffbe2df108e4c.webp</url>
<title>Nautilus Biotechnology Inc</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc</link>
</image>
<item>
<title>Nautilus Biotechnology Reports First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-reports-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-reports-first-quarter-2026-financial-results</guid>
<pubDate>Tue, 28 Apr 2026 12:00:00 GMT</pubDate>
<description>SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Business Highlights Initiated our Iterative Mapping Early Access Program, enabling broader access to our validated Tau proteoform assay, with Baylor College of Medicine as our first customer in a National Institutes of Health-funded cancer study.Ad</description>
</item>
<item>
<title>Nautilus Biotechnology to Announce First Quarter 2026 Financial Results on April 28, 2026</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-to-announce-first-quarter-2026-financial-results-on-april-28-2026</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-to-announce-first-quarter-2026-financial-results-on-april-28-2026</guid>
<pubDate>Thu, 09 Apr 2026 04:00:00 GMT</pubDate>
<description>SEATTLE, April 09, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein</description>
</item>
<item>
<title>Nautilus Biotechnology to Participate in the Investor Summit Group Virtual Conference</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-to-participate-in-the-investor-summit-group-virtual-conference</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-to-participate-in-the-investor-summit-group-virtual-conference</guid>
<pubDate>Tue, 24 Mar 2026 12:00:00 GMT</pubDate>
<description>SEATTLE, March 24, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the Investor Summit Group Virtual Conference. Nautilus’ management is scheduled to present on Wednesday, March 25, 2026, at 10:00 a.m. Pacific Time / 1:00 p.m. Eastern Time. Interested parties may access live and archived webcasts of the presentations on the “Investors” sectio</description>
</item>
<item>
<title>Investor Summit Announces Q1 Presenter Line Up (Presentations 3/25, 1-on-1s 3/26)</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/investor-summit-announces-q1-presenter-line-up-presentations-325-1-on-1s-326-1</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/investor-summit-announces-q1-presenter-line-up-presentations-325-1-on-1s-326-1</guid>
<pubDate>Fri, 20 Mar 2026 12:00:00 GMT</pubDate>
<description>NEW YORK, NY / ACCESS Newswire / March 20, 2026 / The Investor Summit today announced the lineup of public companies scheduled to present at its upcoming Virtual March 25-26, 2026 event. Event Details: Virtual Presentations on Wednesday March 25, ...</description>
</item>
<item>
<title>Nautilus Biotechnology Announces Baylor College of Medicine as First Early Access Program Customer for Voyager Platform</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-announces-baylor-college-of-medicine-as-first-early-access-program-customer-for-voyager-platform</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>• Baylor selects the Nautilus Voyager™ Platform, now available through Early Access Program, for development of a first-in-class computational multi-omics</description>
</item>
<item>
<title>Nautilus Biotechnology Appoints Proteomics Commercial Leader Amber Faust as Vice President of Sales</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-appoints-proteomics-commercial-leader-amber-faust-as-vice-president-of-sales</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-appoints-proteomics-commercial-leader-amber-faust-as-vice-president-of-sales</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>Veteran sales leader with proven proteomics and life sciences track record from Olink and SomaLogic joins Nautilus to accelerate commercial progress of its</description>
</item>
<item>
<title>Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-reports-fourth-quarter-and-fiscal-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-reports-fourth-quarter-and-fiscal-year-2025-financial-results</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>SEATTLE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform,</description>
</item>
<item>
<title>Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-unveils-voyager-platform-enabling-single-molecule-iterative-mapping-at-us-hupo-2026</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-unveils-voyager-platform-enabling-single-molecule-iterative-mapping-at-us-hupo-2026</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>• Revealed core proteomics instrument during US HUPO 2026 following successful field evaluation at the Buck Institute for Research on Aging • Commercial</description>
</item>
<item>
<title>Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-to-participate-in-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-to-participate-in-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Thu, 19 Feb 2026 21:05:00 GMT</pubDate>
<description>SEATTLE, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 46th Annual Health Care Conference. Nautilus’ management is scheduled to participate in a fireside chat on Monday, March 2, 2026, at 10:30 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of</description>
</item>
<item>
<title>Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-announce-fourth-quarter-130000684</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-announce-fourth-quarter-130000684</guid>
<pubDate>Thu, 05 Feb 2026 13:00:00 GMT</pubDate>
<description>SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year 2025 before market open on Thursday, February 26, 2026. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook</description>
</item>
<item>
<title>Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinson’s Disease</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-weill-cornell-medicine-130000569</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-weill-cornell-medicine-130000569</guid>
<pubDate>Wed, 28 Jan 2026 13:00:00 GMT</pubDate>
<description>• Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology • Nautilus’ development of a single-molecule assay for measuring alpha-synuclein proteoforms is its latest application of Iterative Mapping method to uncover new biological insights• Weill Cornell Medicine-Qatar’s deep chemical biology and neurology expertise and field-leading protein standards and affinity reagents position the organizations to probe disease-associ</description>
</item>
<item>
<title>Nautilus Biotechnology Launches Early Access Program for Novel Single-Molecule Proteomics Platform, Starting with Tau Proteoforms Assay</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-launches-early-access-130000495</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-launches-early-access-130000495</guid>
<pubDate>Thu, 08 Jan 2026 13:00:00 GMT</pubDate>
<description>Early Access Program participants receive exclusive use of Nautilus’ Iterative Mapping method, initially through a validated tau proteoforms assay, with the potential to accelerate Alzheimer’s and neurodegenerative disease researchSEATTLE, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering single-molecule proteome analysis, today announced the launch of an Early Access Program for its novel proteomics platform, with a tau proteoform</description>
</item>
<item>
<title>Nautilus Biotechnology Reports Successful Installation and Testing of its First Field Evaluation Unit at the Buck Institute for Research on Aging</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-reports-successful-installation-130000913</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-reports-successful-installation-130000913</guid>
<pubDate>Mon, 03 Nov 2025 13:00:00 GMT</pubDate>
<description>• Buck Institute’s deployment of Nautilus’ instrument generates tau proteoform data, providing external validation of the company’s next-generation single-molecule proteomics platform • Joint research results show high reproducibility across sites and insight into novel tau biology, signaling a fundamental shift in how proteomics technology can advance human health and longevity • Data presentation at the 2025 HUPO World Congress seminar “Redefining Proteomics with Single-Molecule Iterative Mapp</description>
</item>
<item>
<title>Nautilus Biotechnology Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-reports-third-quarter-120000653</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-reports-third-quarter-120000653</guid>
<pubDate>Tue, 28 Oct 2025 12:00:00 GMT</pubDate>
<description>SEATTLE, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Business Highlights Continued progress was made in processing Tau proteoform samples from collaborators in support of our goals of product validation and growing our publications. We expect to share this data at the upcoming World</description>
</item>
<item>
<title>Nautilus Biotechnology to Announce Third Quarter 2025 Financial Results on October 28, 2025</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-announce-third-quarter-120000352</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-announce-third-quarter-120000352</guid>
<pubDate>Tue, 07 Oct 2025 12:00:00 GMT</pubDate>
<description>SEATTLE, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2025 before market open on Tuesday, October 28, 2025. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of t</description>
</item>
<item>
<title>Nautilus Biotechnology to Participate in Upcoming September Investor Conferences</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-participate-upcoming-september-120000978</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-participate-upcoming-september-120000978</guid>
<pubDate>Wed, 27 Aug 2025 12:00:00 GMT</pubDate>
<description>SEATTLE, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences. Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NYManagement is scheduled to participate in a fireside chat on Monday, September 8h at 10:50 a.m. Pacific Time / 1:50 p.m. Eastern Time. Q3 Investor Summit Group Virtual Con</description>
</item>
<item>
<title>Nautilus Biotechnology Reports Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-reports-second-quarter-120000414</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-reports-second-quarter-120000414</guid>
<pubDate>Thu, 31 Jul 2025 12:00:00 GMT</pubDate>
<description>SEATTLE, July 31, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2025. “In Q2, we achieved major milestones that underscore the continued advancement of our platform,” said Sujal Patel, CEO of Nautilus Biotechnology. “Not only did we continue our momentum across both targeted and broadscale proteomic development efforts, b</description>
</item>
<item>
<title>Nautilus Biotechnology Announces Agreement with the Allen Institute, Further Validating its Approach to Single-Molecule Proteomics</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-announces-agreement-allen-120000544</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-announces-agreement-allen-120000544</guid>
<pubDate>Wed, 30 Jul 2025 12:00:00 GMT</pubDate>
<description>• Allen Institute to employ Iterative Mapping, Nautilus’ single-molecule proteomics method, to investigate connection between tau protein and Alzheimer’s disease • Agreement links the organizations’ next-generation proteomics technology and neuroscience leadership to potentially unlock breakthrough therapeutics and biomarkers for neurodegenerative disease SEATTLE, July 30, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering single-molecule pr</description>
</item>
<item>
<title>Nautilus Biotechnology to Announce Second Quarter 2025 Financial Results on July 31, 2025</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-announce-second-quarter-120000160</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-announce-second-quarter-120000160</guid>
<pubDate>Tue, 15 Jul 2025 12:00:00 GMT</pubDate>
<description>SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter 2025 before market open on Thursday, July 31, 2025. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments,</description>
</item>
<item>
<title>Nautilus Biotechnology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-participate-goldman-sachs-120000094</link>
<guid isPermaLink="true">https://6ix.com/company/nautilus-biotechnology-inc/news/nautilus-biotechnology-participate-goldman-sachs-120000094</guid>
<pubDate>Tue, 27 May 2025 12:00:00 GMT</pubDate>
<description>SEATTLE, May 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the Goldman Sachs 46th Annual Global Healthcare Conference. Nautilus’ management is scheduled to participate in a fireside chat on Tuesday, June 10, 2025, at 2:00 p.m. Eastern Time. Interested parties may access a live and archived webcast of the pre</description>
</item>
</channel>
</rss>